Today: 7 February 2026
Subscribe
Browse Category

NYSE:NVS News 16 September 2025 - 31 January 2026

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares surged about 12% to $74.34 in Monday premarket trading after projecting 2025 revenue of $1.27 billion, up 83% from last year. The company reported total contract value over $1.1 billion and signed data deals with more than 70 clients, including major pharmaceutical firms. Northwestern Medicine announced a new partnership with Tempus to expand genomic cancer testing. Tempus’ figures remain preliminary and unaudited.
12 January 2026
······
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI shares rose about 11% in premarket trading Monday after the company reported preliminary 2025 revenue of $1.27 billion, up 83% year-on-year, and record contract value exceeding $1.1 billion. The company cited strong growth in both Diagnostics and Data segments, with over 70 new data agreements signed in 2025. Tempus noted the results are unaudited and subject to change.
12 January 2026
·······
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead. Christmas week trading: shorter sessions, fewer buyers, faster
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3 Below is a comprehensive roundup of the most market-moving healthcare news, plus the latest forecasts and sector analysis shaping how investors are positioning across pharma, biotech, managed care, medtech, and healthcare services into 2026. 1) Drug pricing is
20 December 2025
········
Salesforce (CRM) Stock After Hours Today (Dec. 17, 2025): Qualified Acquisition, Novartis Agentforce Deal, Analyst Forecasts, and What to Watch Before the Market Opens

Salesforce (CRM) Stock After Hours Today (Dec. 17, 2025): Qualified Acquisition, Novartis Agentforce Deal, Analyst Forecasts, and What to Watch Before the Market Opens

Salesforce, Inc. (NYSE: CRM) ended Wednesday, December 17, 2025, on a relative high in a tough tape—then edged lower in after-hours trading as investors processed late-day headlines and looked ahead to a potentially market-moving inflation print Thursday morning. Salesforce stock price after the bell: where CRM stands tonight In regular NYSE trading, Salesforce closed at $258.14, up about 1.27% on the day. In after-hours trading, the stock slipped to roughly $257.50 (down ~0.25%) as of around 6:15 p.m. ET. MarketScreener Wednesday’s session showed a wide—but controlled—trading range for CRM: $256.37 (low) to $261.97 (high), with the stock opening near $256.33.
18 December 2025
··
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Stock Performance & Recent Trends Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the past three months alone, RNA jumped ~40%, fueled by upbeat clinical updates and M&A speculation ts2.tech. The stock hit a 52-week peak of $56 in early October ts2.tech after its lead DMD therapy showed strong results and secured FDA Breakthrough designation. Shares pulled back slightly to around $49 by late October, but remained up 100%+ year-over-year ts2.tech. A major catalyst
27 October 2025
·····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Richmond’s New Pharma Giant: Overview of Lilly’s $5B Factory Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction Washingtonpost. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil Washingtonpost Washingtonpost. Scale and Scope: The plant will
16 September 2025
·······

Stock Market Today

CleanSpark stock price jumps 22% after earnings and AI push — what CLSK traders watch next week

CleanSpark stock price jumps 22% after earnings and AI push — what CLSK traders watch next week

7 February 2026
CleanSpark shares jumped 22% to $10.08 Friday after quarterly results and an AI infrastructure update, following bitcoin’s rebound above $70,000. The company reported a quarterly net loss tied to bitcoin price swings and outlined plans to expand power capacity in Houston. Peers Marathon Digital and Riot Platforms also surged. Upcoming U.S. jobs and inflation data next week could add further volatility.
Nu stock jumps to $17.40 as traders eye Nubank’s next catalyst

Nu stock jumps to $17.40 as traders eye Nubank’s next catalyst

7 February 2026
Nu Holdings shares climbed 3.5% to $17.40 Friday, reversing Thursday’s loss, as the Dow closed above 50,000 for the first time. Nu recently received conditional approval from U.S. regulators to form a national bank, but still needs further sign-offs before launching. The company manages $38.8 billion in deposits and reports earnings Feb. 25.
Go toTop